
List of Figures

#	Title	Page
Figure 1	Global prevalence of obesity worldwide; (A) Occurrence of obesity in 2016; (B) Global death rate in 2017	2
Figure 2	Changes in adipose tissues in an obese individual	5
Figure 3	Maintenance of homeostasis by adipocytes	6
Figure 4	Signalling of the Gut hormone to the brain under fasted and fed states. (A) During the fasting/ pre-prandial state, (B) In the postprandial state	9
Figure 5	Schematic representation of the leptin regulation of food intake and proteins mutated in obesity	10
Figure 6	Pathophysiology of obesity due to the Western Diet	11
Figure 7	Carbohydrate and lipid cycle	12
Figure 8	Strategies to control obesity	13
Figure 9	Fat digestion and absorption	14
Figure 10	Lipid storage and mobilization in adipocytes	16
Figure 11	Common metabolic pathways involved in lipid synthesis in the endoplasmic reticulum and lipid oxidation in mitochondria of the liver and skeletal muscle	17
Figure 12	Secondary structure of the human PL-colipase complex, co-crystallized with Methoxyundecylphosphinic acid (MUP) at the active site (1LPB)	23
Figure 13	Representation of closed (A, B) and open (C, D) lid forms of human PL. A & C represents transparent hydrophobic surface with active site amino acids; B & D includes only hydrophobic surface clearly representing the closed and open lid conformations	24
Figure 14	Schematic flow representing series of biochemical reactions at the catalytic triad of PL during ester hydrolysis	25
Figure 15	Natural product leads and their synthetic products for treatment of metabolic disorder	28
Figure 16	NPs in the patented compositions that target enzymes for anti-obesity effect	34
Figure 17	Enzymatic hydrolysis of p-nitrophenyl butyrate (p-NPB) in absence and presence of inhibitor. (A) PL catalyzed hydrolysis of p-NPB into p-nitrophenol (p-NB) (B) inhibition of PL catalyzed hydrolysis p-NPB ; Low intensity of p-NP and butyrate indicates the presence of strong PL-inhibitor	43

Figure 18	Strategy used for the combination experiments	44
Figure 19	Animal groups for efficacy study of compositions	46
Figure 20	Mechanism of development of obesity using HFD	47
Figure 21	Basic approach to develop BARM-GSM	62
Figure 22	Combination studies of BARM-SO and GSM-SO (A) Dose-effect curve of BARM-GSM for PL inhibition; (B) Combination index plot of BARM-SO and GSM-SO; (C) Isobologram plot of BARM-SO and GSM-SO	64
Figure 23	Basic approach to develop BARM-TSM	65
Figure 24	Combination studies of BARM-SO and TSM-SO (A) Dose-effect curve of BARM-TSM for PL inhibition; (B) Combination index plot of BARM-SO and TSM-SO; (C) Isobologram plot of BARM-SO and TSM-SO	66
Figure 25	Basic approach to develop GSM-TSM	67
Figure 26	Combination studies of GSM-SO and TSM-SO (A) Dose-effect curve of GSM-TSM for PL inhibition; (B) Combination index plot of GSM-SO and TSM-SO; (C) Isobologram plot of GSM-SO and TSM-SO	68
Figure 27	Basic approach to develop AMM-PLM	69
Figure 28	Combination studies of AMM-SO and PLM-SO (A) Dose-effect curve of AMM-PLM for PL inhibition; (B) Combination index plot of AMM-SO and PLM-SO; (C) Isobologram plot of AMM-SO and PLM-SO	70
Figure 29	Dose considered for <i>in vivo</i> analysis	72
Figure 30	Effect of BARM-GSM on (A) bodyweight and (B) liver and abdominal fat content in mice fed with HFD	74
Figure 31	Effect of BARM-GSM on serum lipid profile (A) serum TC (B) serum TG and (C) serum HDL	75
Figure 32	Fecal triglyceride levels determined after treatment with BARM-GSM	76
Figure 33	H&E staining of liver after treatment with BARM-GSM	77
Figure 34	Picrosirius red staining of liver after treatment with BARM-GSM	78
Figure 35	H&E staining of adipose tissues after treatment with BARM-GSM	79
Figure 36	Effect of BARM-TSM on (A) bodyweight and (B) liver and	80

abdominal fat content in mice fed with HFD

Figure 37	Effect of BARM-TSM on serum lipid profile (A) serum TC (B) serum TG and (C) serum HDL	81
Figure 38	Fecal triglyceride levels determined after treatment with BARM-TSM	82
Figure 39	H&E staining of liver after treatment with BARM-TSM	83
Figure 40	Picrosirius red staining of liver after treatment with BARM-TSM	83
Figure 41	H&E staining of adipose tissues after treatment with BARM-TSM	84
Figure 42	Taxonomical classification of <i>B. aristata</i>	88
Figure 43	Chemical constituents (24-32) present in roots of <i>B. aristata</i>	89
Figure 44	Taxonomical classification of <i>G. sylvestre</i>	90
Figure 45	Chemical constituents (33-41) present in leaves of <i>G. sylvestre</i>	91
Figure 46	Hydrolysable product (gymnemagenin) from Gymnemic acid I	92
Figure 47	Taxonomical classification of <i>T. sinensis</i>	92
Figure 48	Catechins (42-45) present in leaves of <i>T. sinensis</i>	93
Figure 49	Taxonomical classification of <i>A. marmelos</i>	93
Figure 50	Chemical constituents (46-54) of <i>A. marmelos</i>	94
Figure 51	Taxonomical classification of <i>P. longum</i>	94
Figure 52	Chemical constituents (55-62) of <i>P. longum</i>	95
Figure 53	Isolation of berberine (25) and palmatine (28) from roots of <i>B. aristata</i>	96
Figure 54	Isolation of ECG (43) and EGCG (45) from leaves of <i>T. sinensis</i>	97
Figure 55	Isolation of alloimperatorin (50) from <i>A. marmelos</i>	98
Figure 56	Isolation of piperine (55) and pellitorine (57) from fruits of <i>P. longum</i>	99
Figure 57	HPLC analysis of BARM-GSM (A) before and (B) after SGF digestion	104
Figure 58	Breakdown of Gymnemic acid I into its aglycone and sugar residues	105
Figure 59	HPLC chromatogram of palmatine, berberine and gymnemagenin	105
Figure 60	HPLC analysis of BARM-TSM (A) before and (B) after SGF	109

	digestion	
Figure 61	HPLC chromatogram of EGCG, ECG, palmatine and berberine	110
Figure 62	HPLC chromatogram of EGCG, ECG, and gymnemagenin	114
Figure 63	HPLC chromatogram of alloimperatorin, piperine and pellitorine	118
Figure 64	Combination study between (A) gymnemagenin-berberine and (B) gymnemagenin -palmatine	125
Figure 65	Combination study between (A) ECG-berberine, (B) ECG-palmatine, (C) EGCG-berberine and (D) EGCG-palmatine	127
Figure 66	Combination study between (A) ECG-gymnemagenin, and (B) EGCG-gymnemagenin	129
Figure 67	Combination study between (A) alloimperatorin-piperine, and (B) alloimperatorin-pellitorine	130
Figure 68	Enzyme kinetics of bio-active markers & Orlistat (A) Berberine, (B) Gymnemagenin, (C) Palmatine, (D) ECG (E) EGCG and (F) Orlistat	133
Figure 69	Enzyme kinetics of (A) piperine, (B) alloimperatorin and (C) pellitorine	134
Figure 70	The Trp residues on the surface of PL enzyme	135
Figure 71	Fluorescence study of (A) berberine; (B) palmatine; (C) gymnemagenin; (D) ECG; (E) EGCG; (F) piperine; (G) pellitorine and (H) alloimperatorin	137
Figure 72	Interaction of Orlistat with PL(I) indicates the best pose obtained from molecular docking; (II) indicates the RMSD plot for 100 ns obtained from Molecular dynamics simulation	141
Figure 73	Interaction of bio-active markers with PL(I) indicates the best pose obtained from molecular docking; (II) indicates the RMSD plot for 50 ns obtained from Molecular dynamics simulation for (A) berberine; (B) palmatine; (C) gymnemagenin (D) ECG; (E) EGCG.	142

List of Tables

#	Title	Page
Table 1	Mechanism of action of the marketed anti-obesity drugs and their adverse effects	3
Table 2	Characteristics of different adipose tissues	7
Table 3	Role of gut-hormones in control of appetite	8
Table 4	HFD Composition for development of obese mice model	45
Table 5	PL inhibition of selected plants using different extraction techniques and organic solvents	55
Table 6	PL inhibition of selected plants using different extraction techniques and water as solvent	56
Table 7	Composition screened for PL inhibition	61
Table 8	Effect of BARM-GSM on lipid profile	76
Table 9	Effect of BARM-TSM on lipid profile	81
Table 10	Summary of optimized HPLC method for the analytes of BARM-GSM	106
Table 11	Precision (% CV) and accuracy (% bias) of the analytes of BARM-GSM	107
Table 12	Method optimization for BARM-GSM: Retention time (R_t) obtained upon making deliberate variation in the chromatographic conditions	108
Table 13	Method optimization for BARM-GSM: HETP and number of theoretical plates (N) obtained upon making deliberate variations in the chromatographic conditions	108
Table 14	Summary of optimized HPLC method for the analytes of BARM-TSM	111
Table 15	Precision (% CV) and accuracy (% bias) of the analytes of BARM-TSM	111
Table 16	Method optimization for BARM-TSM: Retention time (R_t) obtained upon making deliberate variations in the chromatographic conditions	113
Table 17	Method optimization for BARM-TSM: HETP and number of theoretical plates (N) obtained upon making deliberate variations in the chromatographic conditions	113
Table 18	Summary of optimized HPLC method for the analytes of GSM-TSM	115

Table 19	Precision (% CV) and accuracy (% bias) of the analytes of GSM-TSM	116
Table 20	Method optimization for GSM-TSM: Retention time (R_t) obtained upon making deliberate variations in the chromatographic conditions	117
Table 21	Method optimization for GSM-TSM: HETP and number of theoretical plates (N) obtained upon making deliberate variations in the chromatographic conditions	117
Table 22	Summary of optimized HPLC method for the analytes of AMM-PLM	119
Table 23	Precision (% CV) and accuracy (% bias) of the analytes of AMM-PLM	120
Table 24	Method optimization for AMM-PLM: Retention time obtained upon making deliberate variations in the chromatographic conditions	120
Table 25	Method optimization for AMM-PLM: HETP and number of theoretical plates (N) obtained upon making deliberate variations in the chromatographic conditions	121
Table 26	Synergy studies of two drug combination between gymnemagenin, berberine and palmatine	126
Table 27	Synergy studies of two drug combination between ECG, EGCG, berberine and palmatine	128
Table 28	Synergy studies of two drug combination between ECG, EGCG, and gymnemagenin	129
Table 29	Synergy studies of two drug combination between alloimperatorin, piperine and pellitorine	131
Table 30	K_m , V_{max} , and K_i values of Berberine, Palmatine, ECG, EGCG and Orlistat retrieved from the PL enzyme kinetics	133
Table 31	K_m , V_{max} , and K_i values of piperine, alloimperatorin and pellitorine retrieved from the PL enzyme kinetics	134
Table 32	Quenching constant K_A , the binding constant K , the number of binding sites (n) of PL at different temperature	139
Table 33	Thermodynamic parameters of PL at different temperature	140

List of Abbreviations and Symbols

AHA/ACC/TOS	American Heart Association/American College of Cardiology/The Obesity Society
API	Ayurvedic Pharmacopoeia of India
ARF	Alkaloid rich fractions
ATP	Adenosine triphosphate
β -AR	β - Adrenergic Receptor
BAT	Brown Adipose Tissue
BBB	Blood Brain Barrier
BMI	Body Mass Index
CART	Cocaine and amphetamine regulated transcript
CHD	Coronary Heart Disease
CKK	Cholecystokinin
CM	Cold Maceration
CNS	Central Nervous System
CV	Coefficient of Variance
DAG	Diacyl glycerol
DC	Disease control
DCM	Dichloromethane
DM	Diabetes mellitus
DMSO	Dimethyl sulfoxide
DPX	Dibutylphthalate Polystyrene Xylene
EXT	Extract
FDA	Food & Drug Administration
FFA	Free Fatty acid
FOAD	Fetal Origins of Adult Diseases
GABA	Gamma aminobutyric acid
GI	Gastro-Intestinal
GLP-1	Glucagon like peptide type 1 receptor
HDL	High-density lipoproteins

H & E	Hematoxylin & Eosin
HFD	High Fat Diet
HP	Hot Percolation
HPLC	High Performance Liquid Chromatography
HPTLC	High Performance Thin Layer Chromatography
HRMS	High Resolution Mass Spectrometry
IC ₅₀	Half maximal inhibitory concentration
IL	Interleukin
IR	Insulin resistance
KBr	Potassium bromide
KOH	Potassium hydroxide
LCMS	Liquid Chromatography Mass Spectrometry
LD ₅₀	Half maximal Lethal Dose
LDL	Low-density lipoproteins
LOD	Limit of Detection
LOQ	Limit of Quantification
m.p.	Melting point
mmol	Millimole
MAG	Monoacyl glycerol
MC	Extraction by maceration
MCH	Melanin-concentrating hormone
MD	Molecular Dynamics
MM2	Molecular Mechanics 2
MSH	Melanocortin stimulating hormone
MUP	Methoxy undecylphosphonic acid
NMR	Nuclear Magnetic Resonance
NPs	Natural Products
NPY	Neuropeptide Y
NC	Normal control
ND	Normal Diet
nm	Nanometer

NPT	Normal Pressure and Temperature
ns	not significant
NVT	Normal Volume and Temperature
OC	Orlistat control
OXM	Oxyntomodulin
PDB	Protein Data Bank
Pgp	P-glycoprotein
PL	Pancreatic lipase
POMC	Proopiomelanocortin
PPAR	Peroxisome proliferator-activated receptor
PVN	Paraventricular nucleus
P-YY	Peptide-YY
PUFA	Polyunsaturated fatty acid
RMSD	Root Mean Square Deviation
ROS	Reactive oxygen species
rpm	Rotations per minute
RSD	Relative Standard Deviation
RT	Room Temperature
SD	Standard Deviation
SEM	Standard error of mean
SGF	Simulated Gastric fluid
SO	Extraction by ultrasonication
SX	Extraction by soxhlation
TAG	Triacyl glycerol
TC	Total cholesterol
TCA	Tricarboxylic acid
TCM	Traditional Chinese Medicine
TG	Total triglycerides
TLC	Thin Layer Chromatography
UCP-1	Uncoupling protein 1

UK	United Kingdom
US	United States
VLDL	Very low-density lipoproteins
WAT	White adipose tissue
WD	Western Diet
WHO	World Health Organization
WHR	Waist-Hip Ratio
α	Alpha
Å	Angstrom
K_m^{app}	Apparent K_m
β	Beta
dl	Deciliter
°C	Degree Celsius
γ	Gamma
h	Hour
K_i	Inhibitory constant
kg	Kilogram
kcal/mol	Kilocalorie per mole
λ	Lamda
mg	Milligram
μg	Microgram
μM	Micromolar
μl	Microliter
ml	Milliliter
min	Minutes
K_m	Michealis-Menton constant
V_{max}	Maximum velocity
ng	Nanogram
%	Percentage
v/v	Volume/volume
w/w	Weight/weight

List of Equation and Formulae

#	Title	Page
Equation 1	% PL inhibition	43
Equation 2	Combination Index	44
Equation 3	Signal to noise ratio	49
Equation 4	Limit of Detection (LOD)	49
Equation 5	Limit of Quantification (LOQ)	49
Equation 6	Stern-Volmer Equation	50
Equation 7	Number of binding site and binding constant	51
Equation 8	Thermodynamics (temperature Vs. binding constant plot) equation	51
Equation 9	Gibb's Free energy	51
Equation 10	Combination index (general equation)	60
Equation 11	Potency ratio	60
Equation 12	Low density lipoproteins (LDL)	73
Equation 13	Very low-density lipoproteins (VLDL)	73
Equation 14	Michealis-Menton equation	131
Equation 15	Lineweaver and Burk (LB) plot	132
Equation 16	Cheng-Prusoff equation	132
Equation 17	Modified Stern-Volmer equation	138
Equation 18	Thermodynamics equation	139